Choosing the Right Coronary Stent in the Modern Era
详细信息 查看全文
- 作者：Bora Toklu (1)
Sripal Bangalore (2) (3) - 关键词：Bare metal stents ; Coronary artery disease ; Drug ; eluting stents ; Coronary stent
- 刊名：Current Cardiology Reports
- 出版年：2014
- 出版时间：April 2014
- 年：2014
- 卷：16
- 期：4
- 全文大小：582 KB
- 参考文献：1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301:61-. CrossRef
2. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701-. CrossRef
3. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331:489-5. CrossRef
4. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-01. CrossRef
5. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol. 1990;15:1667-7. CrossRef
6. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-1. CrossRef
7. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007;50:1299-04. CrossRef
8. Weisz G, Leon MB, Holmes Jr DR, et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol. 2009;53:1488-7. CrossRef
9. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-8. CrossRef
10. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-8. CrossRef
11. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-02. CrossRef
12. Kuriyama N, Kobayashi Y, Nakama T, et al. Late restenosis following sirolimus-eluting stent implantation. JACC Cardiovasc Interv. 2011;4:123-. CrossRef
13. Park KW, Kim CH, Lee HY, et al. Does "late catch-up" exist in drug-eluting stents: insights from a serial quantitative coronary angiography analysis of sirolimus vs paclitaxel-eluting stents. Am Heart J. 2010;159:446-3. / e443. CrossRef
14. Teeuwen K, Van den Branden BJ, Rahel BM, et al. Late catch-up in lumen diameter at five-year angiography in MACE-free patients treated with sirolimus-eluting stents in the Primary Stenting of Totally Occluded Native Coronary Arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II). EuroIntervention. 2013;9:212-. CrossRef
15. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117,762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873-1. / A meta-analysis of 76 randomized controlled trials of all FDA approved stents showed that DES, both first and second generation, were more efficacious and also as safe when compared with BMS. The prior concerns for increased very late stent thrombosis and decreased safety with first generation DES were refuted. CoCr EES, ZES-R and SES were the most efficacious stents, and CoCr EES were the safety stent with reduction in MI and ST when compared with BMS.
16. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393-02. CrossRef
17. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400-. CrossRef
18. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103:2816-1. CrossRef
19. Bangalore S, Selzer F, Srinivas VS, Williams DO, Faxon DP. Thin vs thick strut stent for percutaneous coronary intervention using bare metal stents: insights from the NHLBI PCI Dynamic Registry. J Am Coll Cardiol. 2010;55:A195.
20. Bangalore S, Selzer F, Williams DO, Faxon DP. Stainless steel vs non-stainless steel stents for percutaneous coronary intervention using bare metal stents: findings from the NHLBI PCI Dynamic Registry. J Am Coll Cardiol. 2010;55:A195.
21. Raber L, Baumgartner S, Garcia-Garcia HM, et al. Long-term vascular healing in response to sirolimus- and paclitaxel-eluting stents: an optical coherence tomography study. JACC Cardiovasc Interv. 2012;5:946-7. CrossRef
22. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-2. CrossRef
23. Kim JS, Kim BK, Jang IK, et al. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). Am Heart J. 2012;163:601-. CrossRef
24. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-. CrossRef
25. Guagliumi G, Ikejima H, Sirbu V, et al. Impact of drug release kinetics on vascular response to different zotarolimus-eluting stents implanted in patients with long coronary stenoses: the LongOCT study (Optical Coherence Tomography in Long Lesions). JACC Cardiovasc Interv. 2011;4:778-5. CrossRef
26. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting vs bare-metal stents. J Am Coll Cardiol. 2006;48:2584-1. CrossRef
27. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352-. CrossRef
28. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803-. CrossRef
29. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58:e44–e122. CrossRef
30. Dangas GD, Claessen BE, Mehran R, Xu K, Stone GW. Stent thrombosis after primary angioplasty for STEMI in relation to nonadherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. EuroIntervention. 2013;8:1033-. CrossRef
31. Gwon HC, Hahn JY, Park KW, et al. Six-month vs 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505-3. CrossRef
32. Valgimigli M, Campo G, Monti M, et al. Short- vs long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015-6. CrossRef
33. Valgimigli M, Borghesi M, Tebaldi M, et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013;34:909-9. CrossRef
34. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510-2
35. Holmvang L, Kelbaek H, Kaltoft A, et al. Long-term outcome after drug-eluting vs bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5?years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2013;6:548-3. CrossRef
36. De Luca G, Stone GW, Suryapranata H, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol. 2009;133:213-2. CrossRef
37. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28:2706-3. CrossRef
38. Pasceri V, Patti G, Speciale G, Pristipino C, Richichi G, Di Sciascio G. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J. 2007;153:749-4. CrossRef
39. Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123:2819-8, 2816 p following 2828.
40. Bangalore S, Amoroso N, Fusaro M, Kumar S, Feit F. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34,068 patient-years of follow-up from randomized trials. Circ: Cardiovasc Interv. 2013;6:378-0. / A meta-analysis of 28 randomized controlled comparison trials in STEMI patients revealed similar safety and better efficacy of each type of DES compared with BMS, therefore, questioning the applicability of BMS utilization in STEMI, which was favored by previous guidelines. Also this analysis found that the second generation DES, specifically CoCr EES, reduced ST rates when compared with BMS.
41. Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent vs bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1-year results of a randomised controlled trial. Lancet. 2012;380:1482-0. CrossRef
42. Group BDS, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-5. CrossRef
43. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-6. CrossRef
44. Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve vs angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56:177-4. CrossRef
45. De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI vs medical therapy in stable coronary disease. N Engl J Med. 2012;367:991-001. CrossRef
46. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60:e44–e164. CrossRef
47. Task Force M, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949-003. CrossRef
48. Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008;337:a1331. CrossRef
49. Boyden TF, Nallamothu BK, Moscucci M, et al. Meta-analysis of randomized trials of drug-eluting stents vs bare metal stents in patients with diabetes mellitus. Am J Cardiol. 2007;99:1399-02. CrossRef
50. Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ. 2012;345:e5170. CrossRef
51. Van de Werf F. Drug-eluting stents in acute myocardial infarction. N Engl J Med. 2006;355:1169-0. CrossRef
52. Cortese B, Bertoletti A, De Matteis S, Danzi GB, Kastrati A. Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomized and observational clinical studies with mid-term follow-up. Int J Cardiol. 2012;161:73-2. CrossRef
53. Pancholy SB, Boruah P, Ahmed I, Kwan T, Patel TM, Saito S. Meta-analysis of effect on mortality of percutaneous recanalization of coronary chronic total occlusions using a stent-based strategy. Am J Cardiol. 2013;111:521-. CrossRef
54. Colmenarez HJ, Escaned J, Fernandez C, et al. Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1854-6. CrossRef
55. Wiisanen ME, Abdel-Latif A, Mukherjee D, Ziada KM. Drug-eluting stents vs bare-metal stents in saphenous vein graft interventions: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2010;3:1262-3. CrossRef
56. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004;110:508-4. CrossRef
57. Amin AP, Reynolds MR, Lei Y, et al. Cost-effectiveness of everolimus - vs paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial). Am J Cardiol. 2012;110:765-0. CrossRef
58. Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013;347:f6625.
59. King L, Byrne RA, Mehilli J, Schomig A, Kastrati A, Pache J. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent vs a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis—test equivalence between two drug-eluting stents (ISAR-TEST) trial. Catheter Cardiovasc Interv. 2013;81:E23-. CrossRef
60. Massberg S, Byrne RA, Kastrati A, et al. Polymer-free sirolimus- and probucol-eluting vs new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: test efficacy of Sirolimus- and Probucol-Eluting vs Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation. 2011;124:624-2. CrossRef
61. Byrne RA, Kastrati A, Tiroch K, et al. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents vs polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol. 2010;55:2536-3. CrossRef
62. Indermuehle A, Bahl R, Lansky AJ, et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomized controlled trials. Heart. 2013;99:327-3. CrossRef
63. Loh JP, Waksman R. Paclitaxel drug-coated balloons: a review of current status and emerging applications in native coronary artery de novo lesions. JACC Cardiovasc Interv. 2012;5:1001-2. CrossRef
64. Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomized, open-label trial. Lancet. 2013;381:461-. CrossRef - 作者单位：Bora Toklu (1)
Sripal Bangalore (2) (3)
1. Virginia Commonwealth University School of Medicine, Richmond, VA, USA
2. Cardiac Catheterization Laboratory, Cardiovascular Outcomes Group, Cardiovascular Clinical Research Center, New York University School of Medicine, New York, NY, USA
3. The Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, NY, 10016, USA - ISSN：1534-3170
文摘
Research and development in the field of coronary stent design is a fast-evolving and fascinating journey. A device that was once introduced to salvage acute closure associated with balloon angioplasty is now the standard of care for many patients with coronary artery disease. Newer generation stents are the product of remarkable progress in technology and innovation, driven by the need to make the stents easier to deliver and to improve their safety and efficacy. As such, the design of these stents has become quite sophisticated and complex. The number of available stents has increased giving patients and physicians more choices on one hand, but also created confusion in selecting the optimal stent for a given patient. Although a ‘one size fits all-approach may not be reasonable, several randomized trials have attested to the efficacy and safety of newer generation durable polymer drug eluting stents. This article discusses the evidence base to support various stent choices in contemporary practice.